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Breast tumors often display extreme genetic heterogeneity characterized by hundreds of gross chromosomal aber-
rations and tens of thousands of somatic mutations. Tumor evolution is thought to be ongoing and driven by
multiplemutagenic processes. Amajor outstanding question iswhether primary tumors havepreexistingmutations
for therapy resistance or whether additional DNA damage and mutagenesis are necessary. Drug resistance is a key
measure of tumor evolvability. If a resistancemutation preexists at the time of primary tumor presentation, then the
intended therapy is likely to fail. However, if resistance does not preexist, then ongoing mutational processes still
have the potential to undermine therapeutic efficacy. The antiviral enzyme APOBEC3B (apolipoprotein B mRNA-
editing enzyme, catalytic polypeptide-like 3B) preferentially deaminates DNA C-to-U, which results in signature
C-to-T and C-to-Gmutations commonly observed in breast tumors. We use clinical data and xenograft experiments
to ask whether APOBEC3B contributes to ongoing breast tumor evolution and resistance to the selective estrogen
receptor modulator, tamoxifen. First, APOBEC3B levels in primary estrogen receptor–positive (ER+) breast tumors in-
versely correlate with the clinical benefit of tamoxifen in the treatment of metastatic ER+ disease. Second, APOBEC3B
depletion in an ER+ breast cancer cell line results in prolonged tamoxifen responses inmurine xenograft experiments.
Third, APOBEC3B overexpression accelerates the development of tamoxifen resistance in murine xenograft
experiments by a mechanism that requires the enzyme’s catalytic activity. These studies combine to indicate that
APOBEC3B promotes drug resistance in breast cancer and that inhibiting APOBEC3B-dependent tumor evolvability
may be an effective strategy to improve efficacies of targeted cancer therapies.
INTRODUCTION
Improvements in the detection and therapy of operable breast tumors
have contributed to a steady decline in mortality (1, 2). Essentially all
breast cancer deaths are caused by metastatic outgrowths that
compromise vital organs, such as the brain, liver, or lungs. Adjuvant
systemic therapies effectively reduce the risk of recurrence at these dis-
tant metastatic sites by treating preexisting, clinically undetectable,
micrometastatic deposits. In estrogen receptor–positive (ER+) breast
cancer, a propensity for late recurrencemore than 5 years after surgery
is well documented and has resulted in recommendations to extend
adjuvant endocrine therapy for a total of 10 years (3, 4). Although en-
docrine therapy may be extended, it is evident that late recurrences
occur even while the patient is taking appropriate therapy (5). The late
recurrence of these apparently dormant metastatic breast cancer cells
may be due to ongoing tumor evolution and acquisition of additional
genetic aberrations.
Mutations are thought to be the major drivers of recurrence,
metastasis, and therapeutic resistance. Recent studies on the molec-
ular origins of mutations in breast cancer have implicated several
molecular mechanisms, including both spontaneous and enzyme-
catalyzed deamination of DNA cytosine bases (6–10) [reviewed by
Swanton et al. (11), Roberts and Gordenin (12), and Helleday et al.
(13)]. The former process correlates with aging and is mostly due to
hydrolytic conversion of 5-methyl cytosine (mC) bases within 5′
NmCG motifs into thymines, which escape base excision repair and
are converted into C-to-T transition mutations by DNA replication
(N = A, C, G, or T). The latter process is attributable to single-stranded
DNA cytosine-to-uracil (C-to-U) deamination catalyzed by one or
more members of the APOBEC3 (apolipoprotein B mRNA-editing
enzyme, catalytic polypeptide-like 3) family of enzymes, characterized
by C-to-T transitions and C-to-G transversions in 5′TCW motifs
(W = A or T).
Human cells have the capacity to express up to seven distinct
APOBEC3 enzymes, which function normally as overlapping innate
immune defenses against a wide variety of DNA-based viruses and
transposons [reviewed by Malim and Bieniasz (14), Stavrou and Ross
(15), and Simon et al. (16)]. APOBEC3A (A3A) and APOBEC3B
(A3B) are leading candidates for explaining APOBEC signature mu-
tations in breast tumors because overexpression of these enzymes
triggers DNA damage responses and inflicts chromosomal muta-
tions in hallmark trinucleotide contexts (7, 17–21). However, endog-
enous A3A is not expressed significantly, nor is its activity detectable
in breast cancer cell lines (7, 22) (see Results). The molecular relevance
of A3A is therefore difficult to assess because the impact of the endog-
enous protein cannot be quantified. In comparison, endogenous A3B
is predominantly nuclear and has been shown to be responsible for
elevated levels of genomic uracil and mutation in multiple breast
cancer cell lines (7, 22). A3B is overexpressed in approximately 50%
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of primary breast tumors (7, 8), and retrospective studies have asso-
ciated elevated A3B mRNA levels with poor outcomes for adjuvant
treatment–naïve ER+ breast cancer cohorts (23, 24). Our original studies
relied on a retrospective prognostic analysis of a treatment-naïve ER+
breast cancer cohort (23); therefore, the observed correlation between
elevated A3B mRNA levels and poor clinical outcomes is consistent
with a variety of therapy-independent intrinsic molecular mechanisms
ranging from indirect models (such as A3B promoting tumor cell
growth) to direct models (such as A3B causing the genomic DNA
damage that results in mutations that fuel ongoing tumor evolution).
A current debate in the cancer field is whether the mutations
that cause therapy resistance preexist in primary tumors (that is,
exist even before diagnosis) or continually accumulate (even after
treatment initiation). In support of the former view, primary tumors
are often composed of billions of cells that are highly heterogeneous,
and deep-sequencing studies have found known drug resistance mu-
tations before therapy initiation [for example, (25–27)]. However,
many studies also support the latter view of ongoing tumor evolu-
tion. For instance, primary tumor deep-sequencing studies often fail
to find evidence for preexisting resistance mutations [for example,
(26, 28)]. Recurrent breast tumors also often have many more so-
matic mutations compared to corresponding primary tumors, sug-
gesting ongoing and cumulative mutational processes (29, 30). In
addition, the subclonal nature of most mutations in breast cancer,
as well as many other cancer types, provides strong evidence for on-
going tumor evolution, including significant proportions of APOBEC
signature mutations (28, 31, 32). Moreover, at the clinical level, the
fact that remission periods in breast cancer can last for many years
strongly suggests that additional genetic changes are required for at
least one remaining tumor cell to manifest as recurrent disease (3, 4).
Here, we test the hypothesis that A3B contributes to ongoing tumor
evolution and to the development of drug resistance mutations in ER+
breast cancer.
RESULTS
Primary breast tumor A3B mRNA levels predict therapeutic
failure upon tumor recurrence
To determine whether A3B contributes to endocrine therapy
resistance, we evaluated the predictive potential of A3B expression
in primary breast tumors from a total of 285 hormone therapy–
naïve breast cancer patients who received tamoxifen as a first-line
therapy for recurrent disease (33). A schematic of the study timeline
is shown in Fig. 1A, and detailed patient characteristics are shown in
table S1. Archived fresh-frozen primary tumor specimens were used
to prepare total RNA, and reverse transcription quantitative poly-
merase chain reaction (RT-qPCR) was used to quantify A3B mRNA
levels. These gene expression results were divided into four quartiles
for subsequent clinical data analysis, with primary tumors of the
upper quartile expressing an average of fourfold to sixfold more A3B
mRNA than those in the lower quartile (dark blue versus red histo-
gram bars, respectively, in Fig. 1B).
The progression-free survival (PFS) durations following recur-
rence and subsequent first-line tamoxifen therapy were compared
for each of the four A3B expression groups. This analysis revealed a
dose-response relationship, with the highest A3B-expressing group
associating with the shortest PFS and with the lowest A3B-expressing
group associating with the longest PFS (Fig. 1C; log-rank, P <
0.0001). The median PFS was 6.2 months for the highest A3B-
expressing group and 14.5 months for the lowest A3B-expressing
group [hazard ratio (HR) 2.40 (1.69 to 3.41); log-rank, P < 0.0001].
This result remained significant for high versus low A3B levels in
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Fig. 1. High A3B levels in primary ER+ breast tumors predict poor response to tamoxifen therapy after tumor recurrence. (A) Schematic of the clinical time course.
Timeline breaks depict variable intervals between clinical milestones. (B) Relative A3B expression levels in each observation group [mean ± SD of n = 72 (quartiles 1 and
3), n = 70 (quartile 2), and n = 71 (quartile 4)]. (C) Kaplan-Meier curves showing the periods of PFS after initiating tamoxifen therapy for patients whose primary tumors
expressed A3B at low (dark blue line), intermediate (light blue and orange lines), or high levels [red line; patient groups and color scheme match those in (B)].
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a multivariate analysis after including the known clinical pathological
predictors of age, disease-free interval, dominant site of relapse, adju-
vant chemotherapy, and ER and progesterone receptor mRNA levels
measured in the primary tumor [HR 2.19 (1.51 to 3.20); log-rank, P <
0.0001; table S2]. These data indicate that primary tumor A3B mRNA
levels are strong and independent predictors of PFS for recurrent ER+
breast cancer treated with tamoxifen. These observations do not sup-
port models in which resistance-conferring mutations preexist in
primary tumors—or disease outcomes would have had no correlation
with A3B expression levels and the data for each quartile group would
have superimposed. Rather, the data support a model in which A3B
promotes the ongoing diversification of residual primary tumor cells
(micrometastatic deposits) that ultimately manifest in the recurrent
setting as acquired resistance, failed tamoxifen therapy, and disease
progression.
Endogenous A3B depletion does not alter the phenotype of
MCF-7L ER+ breast cancer cells in culture
MCF-7 has been used for decades as a unique cell-based model for
ER+ breast cancer research [reviewed by Lee et al. (34)]. Engrafted
MCF-7 tumors are dependent on ER function and therefore are
sensitive to selective ER modulators, including tamoxifen. Further-
more, tamoxifen-induced tumor dormancy (indolence) in this model
system, which can last for several months, frequently leads to drug-
resistant and highly proliferative cell masses. For further studies, in-
cluding animal experiments below, we elected to use the derivative
line MCF-7L because it is tumorigenic in immunodeficient mice
[Ibrahim et al. (35), Sachdev et al. (36), and references therein]
and expresses endogenous A3BmRNA at levels approximating those
found in many primary breast tumors (7). Like most other breast
cancer cell lines, MCF-7L cells have very low levels of A3A and var-
iable levels of other APOBEC3 mRNAs, which have not been impli-
cated in breast cancer mutagenesis (fig. S1).
We initially asked whether endogenous A3B depletion alters
molecular or cellular characteristics of MCF-7L. Cells were trans-
duced with an A3B-specific short hairpin RNA (shRNA) construct
(shA3B) or a nonspecific shRNA construct as a control (shCON) (7),
and uniform shRNA-expressing pools were selected using the linked
puromycin resistance gene. In all shA3B-transduced pools, a robust
>25-fold depletion of endogenous A3BmRNA was achieved (Fig. 2A).
Moreover, the depletion of A3B mRNA was mirrored by a corres-
ponding ablation of all measurable DNA cytosine deaminase activities
from whole-cell and nuclear extracts (Fig. 2B). Although several other
APOBEC family member genes are expressed in MCF-7L, their pro-
tein levels are likely too low to detect using this assay (A3A, A3D,
A3G, and A1), the enzyme is not active on DNA (A2), and/or their
single-stranded DNA cytosine deaminase activity is not evident in
cellular extracts (A3C and A3F) (7, 22). At the microscopic level,
shA3B- and shCON-expressing cells were visibly indistinguishable
(Fig. 2C). The two cell populations showed nearly identical growth
rates and doubling times in cell culture (Fig. 2, D and E). These
results are consistent with A3B knockdown data using the same
shRNA construct in other breast cancer cell lines (7, 22) and with
the observation that A3B is a nonessential human gene (37).
A3B is required for the development of tamoxifen-resistant
tumors in mice
The clinical data reported in Fig. 1 support a model in which A3B
is responsible for precipitating the mutations that promote tamox-
ifen resistance. To directly test this model, we performed a series of
xenograft experiments using MCF-7L pools in which endogenous
A3B was left intact (shCON) or was depleted with the specific
shRNA described above (shA3B). For each condition, 5 million
cells were injected subcutaneously into the flank regions of a cohort
of 5-week-old immunodeficient mice, and tumors were allowed to
reach a volume of approximately 150 mm3. At this point, typically
40 to 50 days after engraftment, the mice in each experimental
group were randomly assigned into two subcohorts, one to receive
daily tamoxifen injections and the other to be observed in parallel
as a control (schematic of experimental design in Fig. 3A).
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Fig. 2. Endogenous A3B depletion does not alter MCF-7L ER+ breast cancer
cells in culture. (A) A3B mRNA levels in MCF-7L cells expressing shA3B or shCON
constructs (TBP, TATA-binding protein mRNA; each bar represents the mean ± SD
of three RT-qPCR assays). (B) A3B DNA cytosine deaminase activity in soluble
whole-cell (W), cytoplasmic (C), and nuclear (N) extracts of MCF-7L cells
expressing shA3B or shCON constructs. Vector (V) and A3B-transfected 293T cell
lysates were used as controls (S, substrate; P, product). (C) Light microscopy
images of shA3B and shCON expressing MCF-7L pools. (D and E) Growth kinetics
and doubling times of cultured MCF-7L cells expressing shA3B versus shCON
constructs (mean ± SD of n = 6 cultures per condition).
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Control-transduced MCF-7L cells formed large 1000-mm3 tu-
mors within 100 days after engraftment and, interestingly, A3B
knockdown caused a modest delay in tumor growth (open blue
versus open orange symbols in Fig. 3B; linear mixed model, F test,
P = 0.002). This result differed from the near-identical growth rates
in cell culture (Fig. 2, D and E) and may be due to the likelihood
that additional adaptations/mutations are required for monolayer/
plastic-conditioned cells to be able to grow optimally as tumors in
mice. As expected, tamoxifen treatment attenuated the growth of
both engineered pools (filled orange and blue symbols in Fig. 3B).
However, control-transduced cells rapidly developed resistance to ta-
moxifen and grew into large tumors, whereas the growth of the A3B-
depleted cell masses was mostly suppressed by tamoxifen over the
year-long duration of this representative experiment (filled orange
versus blue symbols in Fig. 3B; linear mixed model, F test, P <
0.0001). Similar outcomes were observed in additional experiments
(for example, fig. S2).
Xenograft tumor A3B mRNA levels were analyzed by RT-qPCR,
and, in all instances, the intended knockdown or control mRNA
level was found to be durable and maintained through the entire du-
ration of the experiment (Fig. 3C). This series of control experiments
also revealed that endogenous A3B mRNA levels increase in control
shRNA–transduced tumor masses in comparison to the same cells
before engraftment (Fig. 3C). The mechanism for A3B induction
in immunodeficient mice is not known but is unlikely to be due to
estrogen (figs. S3 and S4), as suggested by a recent report (38). Rep-
resentative xenografts were recovered in culture, and the tamoxifen-
resistant phenotype was reconfirmed (for example, Fig. 3D). These
results are fully supportive of a mechanism in which endogenous
A3B causes an inheritable drug resistance phenotype (addressed fur-
ther below). It is notable that endogenous A3B mRNA levels in this
system are comparable to those observed in a large proportion of
primary tumors [approximately 0.1 to 0.2 relative to TBP mRNA
levels in cultured MCF-7L cells (Fig. 2B), 0.4 relative to TBP in ani-
mal tumors described here (Fig. 3C and fig. S3), and a range of 0 to
1.25 and a median of 0.25 relative to TBP in primary breast tumors
previously documented using the same RT-qPCR assay (7)].
A novel lentivirus-based system enables A3B overexpression
in any cell type
We next developed a conditional A3B overexpression system to fur-
ther test the A3B mutagenesis model. A conditional approach is re-
quired because A3B expression in virus-producing cells causes lethal
mutagenesis of retroviral complementary DNA intermediates during
reverse transcription (39–42), and excessive levels of cellular A3B
have the potential to inflict genomic DNA damage that ultimately
leads to cytotoxicity (7, 18, 19). We therefore developed a novel lenti-
viral construct that will only express A3B upon transduction into sus-
ceptible target cells (Fig. 4A). This construct mitigates viral toxicity
issues because it is inactive in virus-producing cells as a result of dis-
ruption of the antisense A3B open reading frame with a sense strand
intron, and it is only expressed after intron removal by splicing in the
virus-producing cells and reverse transcription and integration of the
full proviral DNA in susceptible target cells. It also mitigates toxicity
issues for target cell populations because expression levels are not
excessive (see below). In parallel, an A3B catalytic mutant derivative
(E255Q) was created by site-directed mutagenesis to serve as a neg-
ative control.
Transducing viruses were made by plasmid transfection into 293T
cells with appropriate retroviral helper plasmids encoding Gag, Pol,
and Env (vesicular stomatitis virus glycoprotein). As anticipated, no
producer cell toxicity was observed, and A3B and A3B-E255Q viral
titers were equivalent by RT-qPCR. MCF-7L cells were transduced
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Fig. 3. A3B is required for the development of tamoxifen-resistant tumors in
mice. (A) Schematic of the A3B knockdown xenograft study design and time
course (see text for details). (B) Growth kinetics of engrafted MCF-7L cells
expressing shA3B or shCON in the absence or presence of tamoxifen (TAM) treatment.
Tumor volumes were measured weekly (mean + SEM shown for clarity of data presen-
tation). (C) A3B mRNA levels in xenografted tumors recovered from the experiment
shown in (B) (TBPmRNA; each bar represents the mean ± SD of three RT-qPCR assays).
(D) MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] data compar-
ing tamoxifen susceptibility of input MCF-7L cells versus tamoxifen resistance of a
representative MCF-7L shCON tumor [tamoxifen (10, 100, and 1000 ng/ml)].
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with each virus stock, and puromycin selection was used to eliminate
nontransduced cells and to ensure 100% transduction efficiencies.
A3B quantification by RT-qPCR showed that each construct elevates
mRNA expression to levels approximately 10-fold higher than those
of the reference gene TBP (Fig. 4B), which equate to levels approxi-
mately 50-fold higher than those of the endogenous A3B expressed
in this system. These A3B mRNA levels are similar to those found
in the top fraction of breast tumors and cancer cell lines [Burns
et al. (7), Leonard et al. (22), Sieuwerts et al. (23), and this study].
As for the A3B knockdown experiments above, A3B- and A3B-
E255Q–overexpressing MCF-7L populations showed no overt signs
of toxicity and indistinguishable growth rates (Fig. 4C).
Overexpression of catalytically active A3B accelerates the
development of tamoxifen-resistant tumors
To further test the model in which A3B provides mutagenic fuel for
tumor evolution and drug resistance, we performed a series of
xenograft experiments using MCF-7L cells transduced with the
aforementioned constructs and thereby overexpressing wild-type
A3B or the catalytic mutant derivative A3B-E255Q (Fig. 5A). Im-
munodeficient animals were injected subcutaneously with 5 million
cells and, upon palpable tumor growth (150 mm3), randomly
divided into groups for tamoxifen injections or control observation.
Remarkably, most of the cell masses overexpressing A3B developed
rapid resistance to tamoxifen (filled red symbols in Fig. 5B). In
comparison, MCF-7L cells expressing equivalent levels of A3B-
E255Q mutant mRNA showed resistance kinetics similar to those
of the shCON engraftments described above (filled orange symbols
in Fig. 5B; linear mixed model, F test, P = 0.015). An independent
experiment yielded similar results (fig. S5). These data demonstrate
that A3B overexpression accelerates the kinetics of the development
of tamoxifen resistance and, notably, that this phenotype requires
catalytic activity.
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ESR1 mutations are not responsible for tamoxifen resistance
in the MCF-7L model for ER+ breast cancer
Although the development of tamoxifen-resistant breast tumors is
a major clinical problem, in most cases the molecular basis for
resistance is unknown. A small fraction of treated patients develop
tumors with ESR1 exonic mutations that cause amino acid changes
in the hormone-binding domain of the ER. These mutations have
been seen mostly in tumors resistant to aromatase inhibitors and
not as frequently in tumors resistant to tamoxifen [reviewed by
Clarke et al. (43) and Jeselsohn et al. (44)]. To determine whether
ESR1 mutations are also part of the tamoxifen resistance mecha-
nism in MCF-7L cells, we performed DNA exome sequencing on
9 independent tamoxifen-resistant xenografts and 10 independent
control tumor masses. The ESR1 gene contained no mutations un-
der either condition (see table S3 for a full list of base substitution
mutations). Resistant tumor ESR1 mRNA levels were somewhat
variable but still similar to those present in the original MCF-7L
cell populations (fig. S6). Together with the data presented above
indicating heritable resistance to tamoxifen (Fig. 3D), these results
suggest that at least one other resistance mechanism occurs in the
MCF-7 model system for ER+ breast cancer.
DISCUSSION
The clinical and xenograft results presented here strongly support a
model in which A3B drives tamoxifen resistance in ER+ breast
cancer. Clinically, resistance to endocrine therapies has been defined
as primary or secondary, depending on the length of time a patient
benefits from ER-targeted therapy. Our data suggest that A3B may
have a role in both kinds of resistance and particularly in the develop-
ment of secondary, acquired resistance. Suppression of endogenous
levels of A3B enhances tamoxifen benefit (Fig. 3), whereas overex-
pression of A3B eliminates almost all benefits from tamoxifen ther-
apy (Fig. 5). Because the only known biochemical activity of A3B is
single-stranded DNA cytosine deamination [for example, (7, 42, 45)]
and the tamoxifen resistance phenotype is heritable (Fig. 3D), the
most likely mechanism is A3B-catalyzed DNA C-to-U editing coupled
to the processing of these uracil lesions into somatic mutations by
normal DNA repair processes [reviewed by Swanton et al. (11), Roberts
and Gordenin (12), and Helleday et al. (13)]. In further support of this
mechanism, the catalytic glutamate of A3B (E255) is required for
accelerated tamoxifen resistance kinetics upon enzyme overexpression.
Because ESR1mutations were not observed in MCF-7L tamoxifen-
resistant tumors, the identity of the resistance-conferring mutations
in this system will require significant future studies and possibly even
whole-genome sequencing if the predominant causal lesions lie out-
side the exomic fraction of the genome. The intrinsic signature of
A3B may help to identify candidate (frequently mutated) sites for
mechanistic follow-up. Then, for instance, genetic knock-in experi-
ments could be used to unambiguously establish a cause-effect re-
lationship. However, the resistance-conferring mutations (such as
gene translocations, amplifications, or deletions) could also be complex
and difficult to recapitulate precisely because DNA repair enzymes
can readily process genomic uracil lesions into single- and double-
stranded breaks (46, 47).
A3Bhas been implicated as a dominant source ofmutation in breast,
head/neck, lung, bladder, and cervical cancers and—to a lesser but still
significant extent—in many other tumor types (7–10, 28, 32, 48, 49).
The fundamental nature of theDNAdeaminationmechanism, together
with the data presented here, strongly suggests that A3B may be a gen-
eral mechanism of therapeutic resistance to cancer therapy. At this
point, potential mutagenic contributions from other APOBEC3 family
members, such as A3A, cannot be excluded fully, but they do not ap-
pear to manifest in the MCF-7L system, nor are these potential contri-
butions large enough to prevent the significant association between
A3B expression levels and clinical outcomes for ER+ breast cancer
patients [treatment-naïve data in the studies by Sieuwerts et al. (23)
and Cescon et al. (24) and post-recurrence tamoxifen resistance data
in Fig. 1]. Thus, strategies to down-regulate A3B activity or expression,
as reported here using a specific shRNA knockdown construct in a
model system for ER+ breast cancer, may be beneficial as chemo-
therapeutic adjuvants to “turn down” the mutation rate, decrease the
likelihood of evolving drug resistance, and prolong the clinical benefit
of therapy for the many cancers that are likely to be driven by this
ongoing mutational process.
MATERIALS AND METHODS
Clinical studies
The clinical characteristics of the 285 patients [225 from Rotterdam
(Erasmus University Medical Center) and 60 from Nijmegen (Radboud
University Medical Center)] whose primary tumor specimens and data
were used here have been described previously by Sieuwerts et al. (33).
The protocol to study biological markers associated with disease out-
come was approved by the medical ethics committee of the Erasmus
University Medical Center (Rotterdam, Netherlands) (MEC 02.953);
for Nijmegen, coded primary tumor tissues were used in accordance
with the Codes of Conduct of the Federation of Medical Scientific So-
cieties in the Netherlands (www.federa.org/codes-conduct). Thirty-
two patients presented with distant metastasis at diagnosis or developed
distant metastasis (including supraclavicular lymph node metastasis)
within 1 month following primary surgery (M1 patients). These 32
patients and the 253 patients who developed a first recurrence during
follow-up (25 patients with local-regional relapse and 228 patients
with distant metastasis) were treated with first-line tamoxifen. All pa-
tients were ER+ and anti–hormonal therapy–naïve, but 38 patients
received adjuvant chemotherapy. The median time between the
primary surgery and the start of therapy was 24 months (range, 0
to 120 months). The median follow-up of patients alive at the end of
follow-up was 98 months (range, 9 to 240 months) after the primary
surgery and 45 months (range, 3 to 178 months) after the start of
first-line tamoxifen therapy. For 182 patients (64%), disease progres-
sion occurred within 6 months of the start of the first-line therapy
being controlled by tamoxifen. At the end of the follow-up period,
268 (94%) patients had developed tumor progression, and 222
(78%) patients had died.
Total RNA was extracted with RNA Bee (Tel Test, Thermo Fisher
Scientific Inc.) from 30-mm fresh-frozen primary tumor tissue sections
containing at least 30% invasive tumor cell nuclei, and mRNA tran-
scripts were quantified by RT-qPCR as described previously by Sieuwerts
et al. (23). The median A3B expression level in the group of 285 breast
cancers was 0.22 relative to the normalized average of three reference
genes [HPRT1, HMBS, and TBP (23)].
DNA constructs
A3B knockdown and control shRNA constructs were described and
validated previously by Burns et al. (7) and Leonard et al. (50). The
A3B and A3B-E255Q lentiviral expression constructs were based
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on the pLenti4TO backbone (Life Technologies). Overlapping PCR
was used to place a sense-encoded intron between an antisense-
encoded A3B open reading frame (primers available on request). A
cytomegalovirus promoter drove A3B expression, and a simian virus
40 early promoter drove puromycin resistance. Constructs were ver-
ified by DNA sequencing.
Cell culture studies
MCF-7L cells were cultured at 37°C under 5% CO2 and maintained
in improved minimum essential medium (Richter’s modification
medium) containing 5% fetal bovine serum, penicillin (100 U/ml),
streptomycin (100 mg/ml), and 11.25 nM recombinant human in-
sulin. These cells were originally obtained from C. Kent Osborne
(Baylor College of Medicine, Houston, TX) and are subject to short
tandem repeat analysis yearly to confirm their identity with the
original MCF-7 cell line. Cells were transduced with the lentivirus-
based shRNA or conditional expression constructs described above
and selected with puromycin (1 mg/ml; United States Biological) for
72 hours to generate uniformly transduced pools. Cell growth ex-
periments were performed by plating 100,000 cells per six-well plate
and incubating them at 37°C for the indicated days. Cells were tryp-
sinized, diluted 1:2 in trypan blue (Invitrogen), and counted via a he-
mocytometer (six biological replicates per day per condition). Cell
proliferation rates were determined using the xCELLigence real-time
cell analyzer dual-plate instrument according to the manufacturer’s
instructions (ACEA Biosciences).
The mRNA level of eachAPOBEC family member gene was quan-
tified using previously described RT-qPCR protocols and primer/
probe combinations and presented relative to the housekeeping gene
TBP (7, 51, 52). ESR1 andC-MYCRNAwere quantified by RT-qPCR
using intron-spanning primers 5′-ATGACCATGACCCTCCA-
CACC and 5′-TCAGACCGTGGCAGGGAAACC (UPL24) and
5′-GCTGCTTAGACGCTGGATTT and 5′-TAACGTTGAGGGG-
CATCG (UPL66), respectively, and manufacturer-recommended
protocols (LightCycler 480, Roche). C-MYC is an established estrogen-
responsive gene (53).
DNA deaminase activity was measured in soluble whole-cell,
nuclear, and cytoplasmic fractions of MCF-7L cultures using
established protocols (7, 54). The single-stranded DNA substrate
contained a single target cytosine (5′-ATTATTATTATTC-
GAATGGATTTATTTATTTATTTATTTATTT-fluorescein); de-
amination, uracil excision, and backbone cleavage resulted in a
single faster-migrating product on SDS–polyacrylamide gel electro-
phoresis and image analysis (Typhoon FLA 7000 and ImageQuant
software, GE Healthcare Life Sciences).
Xenograft studies
The University of Minnesota Institutional Animal Care and Use
Committee approved the animal protocols used here (1305-
30638A). MCF-7L cells were harvested at 70% confluence, counted,
and resuspended in serum-free medium (without phenol red) at a
concentration of 5 million cells per 50 ml of final volume. Ovariec-
tomized, athymic mice (Harlan) were injected subcutaneously in
the left flank with 50 ml of cell suspension at approximately 5 weeks
of age. Each experiment was initiated with 5 or 10 mice per exper-
imental condition. One week before injection and at all times fol-
lowing, the mice were provided with drinking water supplemented
with 1 mM b-estradiol (Sigma-Aldrich) (except for the subset of
mice used in the experiment shown in fig. S3). Tumors were measured
bidirectionally twice weekly, and tamoxifen treatment began when the
average tumor volume reached 150 mm3. Tamoxifen citrate (500 mg;
Sigma-Aldrich) emulsified in 50 ml of peanut oil was administered
subcutaneously 5 of 7 days each week. Tumor volumes were calculated
using the following formula: length × breadth2/2.
MCF-7L exome sequencing
GenomicDNAwas prepared from tumor cellmasses (~20mg per sam-
ple) via the Gentra Puregene Tissue DNA isolation protocols (Qiagen).
Samples were diluted to 100 ng/ml and assessed further for quality and
purity by SYBRGreenPCRon a 197-bp fragment ofA3H using primers
5′-CATGGGACTGGACGAAGCGCA and 5′-TGGGATCCACACA-
GAAGCCGCA. Samples with no amplification were excluded from
the analysis. One microgram of total genomic DNA per sample was
subjected to whole-exome sequencing on the Complete Genomics
platform to an average target depth of 100× (BGI). Reads were
aligned by BGI using its in-house pipeline, and the alignments in bam
format were used for variant calling. Somatic variants were called for
each tumor alignment by VarScan 2 (55) using an estrogen-treated
shA3B sample as the normal control. The variants were filtered with a
minimum overall coverage depth of 20 reads and a minimum coverage
depth of 4 reads for the alternate allele. Any variant occurring at any
frequency above 0 at the same position in more than one sample was
considered a common mutation in the input pool and was removed.
A full list of base substitution mutations is provided in table S3.
Statistics
Comparisons of the PFS of hormone-naïve breast cancer patients
following treatment for first recurrence with tamoxifen, by A3B ex-
pression level (divided into quartiles), were conducted using log-
rank tests; HRs and 95% confidence intervals are presented for
pairwise comparisons. Clinical data were analyzed using SPSS Sta-
tistics version 23.0 (IBM). In the xenograft studies, repeated mea-
sures of tumor volume over time were compared by treatment
group using linear mixed models with fixed effects for treatment,
days, and interaction between treatment and days and with random
intercept and slope effects for each mouse. P values <0.05 were
considered statistically significant. Xenograft data were analyzed
using Prism 6 and SAS 9.3.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/2/10/e1601737/DC1
fig. S1. APOBEC family member expression in MCF-7L cells.
fig. S2. Replica A3B knockdown xenograft experiment.
fig. S3. Estrogen does not affect A3B mRNA levels in engrafted MCF-7L cells.
fig. S4. A3B is not estrogen-inducible.
fig. S5. Replica A3B overexpression xenograft experiment.
fig. S6. ESR1 mRNA levels in tamoxifen-resistant MCF-7L cells.
table S1. Patient characteristics and median and interquartile range of APOBEC3B mRNA levels.
table S2. Cox univariate and multivariate analyses for PFS after initiating first-line tamoxifen.
table S3. Single-base substitution mutations in tamoxifen-resistant tumors (separate Microsoft
Excel file).
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